Results 51 to 60 of about 38,769 (305)

Navigating the therapeutic landscape of SGLT2 inhibitors in diabetes management: exploring efficacy and emerging concerns [PDF]

Exploration of Medicine
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are integral to diabetes treatment, facilitating renal glucose excretion and offering benefits in cardiovascular risk reduction, kidney function preservation, and weight management.
Farazul Hoda, Harsha Negi, Digvijaya Saini, Mawrah Arshad, Sidra Zayed, Mukesh Kumar Raut, Mohammad Anwar Habib, Mohd Akhtar, Abul Kalam Najmi   +8 more
doaj   +1 more source

Review on SGLT2 Inhibitors

Asian Journal of Pharmaceutical Research and Development, 2023
The pharmaceutical industry employs a variety of analytical techniques to test the quality, concentration, and composition of medicines in biological fluids. This review work to provide the most existing analytical methods for the analysis of SGLT2 inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin) in active pharmaceutical ingredients, biological
Pravin Dighe, Namrata Kale
openaire   +1 more source

SGLT2 Inhibitors for Nephrologists

EMJ Nephrology, 2022
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are the mainstay of therapy for the prevention of progressive renal damage in diabetic and non-diabetic kidney diseases, especially glomerulonephritides. Sodium-glucose co-transporter-2 inhibitors are a relatively new class of oral antidiabetic drugs.
Mufti Baleegh-ur-Raheem Mahmood, Sidra Farishta   +1 more
openaire   +2 more sources

The Impact of SGLT2 Inhibitors on Hemoglobin Levels in Type 2 Diabetes: Potential Benefits Beyond Glycemic and Renal Outcomes [PDF]

Aim: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are antidiabetic agents with proven cardiovascular and renal benefits. Recent evidence suggests they may also increase hemoglobin (Hb) levels through mechanisms beyond hemoconcentration.
Nilsu Kalayci, Emre Hoca
core   +1 more source

Glucose Lowering and Metabolic Effects of SGLT2 Inhibitors [PDF]

, 2022
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have consistently demonstrated improved outcomes in patients with heart failure with or without type 2 diabetes however the mechanisms contributing to these benefits remain poorly understood. While SGLT2
Lang, Chim C.; id_orcid, Mordi, Ify R.; id_orcid   +1 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition

Scientific Reports, 2017
Carbasugar sodium-glucose cotransporter 2 (SGLT2) inhibitors are highly promising drug candidates for the treatment of Type 2 diabetes mellitus (T2DM). However, the clinical usage of carbasugar SGLT2 inhibitors has been underexplored, due to the lengthy ...
Wai-Lung Ng, Ho-Chuen Li, Kit-Man Lau, Anthony K. N. Chan, Clara Bik-San Lau, Tony K. M. Shing   +5 more
doaj   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

The effects of sodium-glucose cotransporter-2 inhibitors in chemotherapy-induced cardiotoxicity and mortality in patients with cancer: a systematic review and meta-analysis

Cardio-Oncology
Background The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on reducing cardiovascular events in different subgroups of diabetic patients are under investigation. The current systematic review and meta-analysis investigated the effects of
Tara Reshadmanesh, Reza Mohebi, Amir Hossein Behnoush, Azadeh Reshadmanesh, Amirmohammad Khalaji, Mitra Norouzi, Elmira Javanmardi, Reza Pishdad, S. Reza Jafarzadeh, Elina Ghondaghsaz, Sandra Chaparro   +10 more
doaj   +1 more source

Sodium-glucose co-transporter 2 (SGLT2) inhibitors [PDF]

, 2020
Type 2 diabetes mellitus is a progressive metabolic disorder. Marked hyperglycaemia leads to serious vascular complications. Hence, addressing this modifiable risk factor is of paramount importance.
Gruppetta, Mark, Mifsud, Simon, Montebello, Annalisa, Schembri, Emma Louise   +3 more
core